Barclays Increases Globus Medical (NYSE:GMED) Price Target to $123.00

Globus Medical (NYSE:GMED) had its price target boosted by research analysts at Barclays from $118.00 to $123.00 in a research note issued on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the medical device company’s stock. Barclays‘s price target suggests a potential upside of 27.22% from the company’s current price.

A number of other equities analysts have also commented on GMED. Needham & Company LLC boosted their price objective on shares of Globus Medical from $112.00 to $114.00 and gave the stock a “buy” rating in a report on Wednesday. TD Cowen raised Globus Medical to a “strong-buy” rating in a research report on Tuesday, January 27th. Bank of America raised Globus Medical from a “neutral” rating to a “buy” rating and increased their price target for the company from $65.00 to $91.00 in a report on Friday, November 7th. BTIG Research restated a “neutral” rating on shares of Globus Medical in a research note on Tuesday, December 30th. Finally, Wall Street Zen upgraded shares of Globus Medical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 3rd. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $104.36.

Globus Medical Stock Up 0.5%

NYSE GMED opened at $96.68 on Wednesday. Globus Medical has a fifty-two week low of $51.79 and a fifty-two week high of $101.40. The business has a 50 day moving average price of $90.52 and a two-hundred day moving average price of $76.13. The stock has a market cap of $12.94 billion, a PE ratio of 24.54, a P/E/G ratio of 1.37 and a beta of 1.06.

Globus Medical (NYSE:GMED) last posted its quarterly earnings data on Tuesday, February 24th. The medical device company reported $1.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.06 by $0.22. Globus Medical had a net margin of 18.30% and a return on equity of 12.57%. The company had revenue of $826.42 million for the quarter, compared to analyst estimates of $803.29 million. During the same quarter last year, the firm posted $0.84 earnings per share. The business’s quarterly revenue was up 25.7% on a year-over-year basis. Sell-side analysts anticipate that Globus Medical will post 3.44 EPS for the current fiscal year.

Insider Buying and Selling at Globus Medical

In other Globus Medical news, CFO Kyle Kline sold 3,594 shares of the stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $101.10, for a total transaction of $363,353.40. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Kelly Huller sold 10,000 shares of Globus Medical stock in a transaction that occurred on Thursday, February 12th. The shares were sold at an average price of $87.67, for a total value of $876,700.00. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 34,136 shares of company stock worth $3,111,033 over the last 90 days. Insiders own 18.51% of the company’s stock.

Institutional Investors Weigh In On Globus Medical

Hedge funds have recently made changes to their positions in the business. SBI Securities Co. Ltd. raised its stake in Globus Medical by 98.2% during the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after acquiring an additional 167 shares in the last quarter. Advisory Services Network LLC acquired a new stake in Globus Medical during the third quarter valued at approximately $26,000. EverSource Wealth Advisors LLC boosted its holdings in Globus Medical by 74.3% during the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after buying an additional 197 shares in the last quarter. Advisors Asset Management Inc. bought a new stake in Globus Medical during the second quarter worth approximately $28,000. Finally, Larson Financial Group LLC grew its position in Globus Medical by 83.4% in the fourth quarter. Larson Financial Group LLC now owns 532 shares of the medical device company’s stock worth $46,000 after buying an additional 242 shares during the last quarter. Institutional investors own 95.16% of the company’s stock.

Key Stories Impacting Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Barclays raised its price target to $123 and kept an overweight rating (largest upside among recent lifts), signaling stronger revenue/earnings confidence. Globus Medical (NYSE:GMED) Given New $123.00 Price Target at Barclays
• Positive Sentiment: Needham increased its target to $114 and reiterated a Buy rating, reflecting upgraded estimates and constructive commentary on spine & robotics growth. Globus Medical (NYSE:GMED) Given New $114.00 Price Target at Needham & Company LLC
• Positive Sentiment: Wells Fargo lifted its target to $104 and moved to an Overweight rating, adding further analyst buying conviction. Benzinga
• Positive Sentiment: Multiple sell-side analysts (TD Cowen, Morgan Stanley, Needham commentary on TipRanks) reiterated Buy/Overweight calls and cited strengthening U.S. spine momentum, margin expansion, and accretion from M&A/robotics as durable catalysts. TD Cowen/TipRanks coverage
• Positive Sentiment: Q4 results beat consensus: EPS of $1.28 vs. ~$1.06 est and revenue ahead of estimates — supporting upward revisions to 2026 EPS and showing double-digit revenue growth year-over-year. Zacks: GMED Surpasses Q4 Earnings and Revenue Estimates
• Positive Sentiment: Company Q4 earnings call highlighted profitable growth and execution on margin expansion and robotics momentum — reinforcing analyst optimism. TipRanks: Earnings Call Shows Profitable Growth
• Neutral Sentiment: Full Q4 earnings call transcript published for investor review (useful for detail but informational rather than a new catalyst). Seeking Alpha: Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Analyst and media write-ups (Zacks/TipRanks) provide deeper metric analysis; helpful for modelling but largely reiterative of the beat and guidance commentary. Zacks: Key Metrics on GMED Q4

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.